| Literature DB >> 31777540 |
Mokhtar Ibrahim Yousef1, Abdelsalam Abdalla Abuzreda1, Maher Abdel-Nabi Kamel2.
Abstract
Engineered nanoparticles (NPs) have been increasingly used in numerous fields over the last decade. In particular, iron oxide NPs (Fe2O3NPs) and silver NPs (AgNPs) have contributed to the current increase in NP usage. However, the possible side effects of increased NP exposure remain not fully elucidated. The present study aimed to assess the toxic effects of Fe2O3NPs and AgNPs, both individually and in combination, on the heart and lungs of male rats. To evaluate the in vivo NP toxic effects, the experimental animals were orally administered with Fe2O3NPs (5 mg/kg) and/or AgNPs (50 mg/kg). Animals were treated every day for 79 days. The results demonstrated that at the molecular level, Fe2O3NPs and AgNPs caused marked DNA base oxidation as indicated by the elevated DNA content of 8-hydroxy-2-deoxyguanosine in the heart and lungs. Fe2O3NPs and/or AgNPs decreased paraoxonase 1, antioxidant enzymes, total antioxidant capacity, and reduced glutathione in heart and lung. A dose-dependent increase in production of creatine kinase, thiobarbituric acid-reactive substances, nitric oxide end products, tumor necrosis factor-α, interleukin-6 and lipid profiles was detected. Histological changes were also evident in heart and lung tissues. The two NPs demonstrated similar toxic effects for the majority of factors when co-supplemented. In conclusion, the present study identified that Fe2O3NPs and AgNPs, alone and in combination, induced cardiotoxicity and lung toxicity. Furthermore, findings demonstrated that there was a greater toxic effect due to administration of both NPs compared to individual administration. It was hypothesized that the toxic effects may be mediated through the induction of oxidative DNA damage, lipid peroxidation, shifting redox status, disrupted gene expression, and deregulation in cytokine production. Copyright: © Yousef et al.Entities:
Keywords: 8-hydroxy-2′-deoxyguanosine; cardiotoxicity; cytokines; iron oxide nanoparticles; lung toxicity; oxidative stress; p53; silver nanoparticles
Year: 2019 PMID: 31777540 PMCID: PMC6862265 DOI: 10.3892/etm.2019.8108
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.Content of 8-OHdG in control, Fe2O3NP-exposed group, AgNP-exposed group, and Fe2O3NP and AgNP-coexposed group. (A) Cardiac and (B) lung tissue 8-OHdG levels measured using ELISA. *P<0.05 vs. control group; #P<0.05 vs. Fe2O3NP-exposed group; $P<0.05 vs. AgNP-exposed group; &P<0.05 synergistic interactions when both NPs are combined using Factorial Design. 8-OHdG, 8-hydroxy-2′-deoxyguanosine; Fe2O3NP, iron oxide nanoparticle; AgNP, silver nanoparticle.
Figure 2.Levels of inflammatory cytokines in control, Fe2O3NP-exposed group, AgNP-exposed group, and Fe2O3NP and AgNP-coexposed group. (A) Levels of p53 in rat cardiac and (B) lung tissues. (C) TNF-α levels in rat cardiac and (D) lung tissues. (E) Levels of IL-6 in rat cardiac and (F) lung tissues. *P<0.05 vs. control group; #P<0.05 vs. Fe2O3NP-exposed group; $P<0.05 vs. AgNP-exposed group; &P<0.05 synergistic interactions when both NPs are combined using Factorial Design. Fe2O3NP, iron oxide nanoparticle; AgNP, silver nanoparticle; TNF-α, tumor necrosis factor- α; IL, interleukin.
Heart and lung tissues levels of TBARS, NOx, GSH, SOD, CAT, GST, GPx and TAC of male rats exposed to Fe2O3NPs and AgNPs.
| A, Heart tissues | ||||
|---|---|---|---|---|
| Experimental groups | ||||
| Parameter | Control | Fe2O3NPs | AgNPs | Fe2O3NPs+AgNPs |
| TBARS (nmol/g tissue) | 59.9±1.2 | 78.8±1.4[ | 87.5±3.4[ | 116.4±3.6[ |
| NO (µmol/g tissue) | 28.24±0.74 | 33.35±0.30[ | 40.78±2.5[ | 47.80±0.27[ |
| GSH (nmol/g tissue) | 5.0±0.20 | 3.7±0.27[ | 4.0±0.06[ | 3.3±0.14[ |
| SOD (mU/mg protein) | 38.3±2.2 | 24.3±1.6[ | 25.4±1.7[ | 16.2±0.8[ |
| CAT (U/mg protein) | 55.0±2.94 | 40.0±1.11[ | 38.0±1.88[ | 18.0±0.89[ |
| GST (U/mg protein) | 0.46±0.03 | 0.36±0.01[ | 0.32±0.02[ | 0.29±0.01[ |
| GPX (mU/mg protein) | 26.6±1.81 | 18.4±1.18[ | 17.1±1.29[ | 13.4±0.63[ |
| TAC (µmol/g tissue) | 21.50±0.10 | 17.27±0.31[ | 17.08±0.16[ | 14.14±0.12[ |
| TBARS (nmol/g tissue) | 41.0±1.5 | 75.2±2.1[ | 70.6 ± 0.9[ | 89.5±2.7[ |
| NO (µmol/g tissue) | 36.6±1.73 | 51.8±0.81[ | 69.7±0.73[ | 75.6±0.57[ |
| GSH (nmol/g tissue) | 5.7±0.13 | 4.7±0.21[ | 4.4±0.24[ | 3.5±0.18[ |
| SOD (mU/mg protein) | 9.0±0.2 | 6.7±0.2[ | 7.2±0.1[ | 4.4±0.2[ |
| CAT (U/mg protein) | 42.9±0.85 | 28.5±1.16[ | 27.1±1.66[ | 15.5±0.87[ |
| GST (U/mg protein) | 0.57±0.02 | 0.44±0.01[ | 0.41±0.01[ | 0.35±0.02[ |
| GPX (mU/mg protein) | 33.8±0.844 | 25.1±0.976[ | 26.1±0.901[ | 18.6±0.879[ |
| TAC (µmol/g tissue) | 22.8±0.02 | 21.1±0.13[ | 18.7±0.07[ | 16.3±0.07[ |
P<0.05 vs. control group
P<0.05 vs. Fe2O3NP-exposed group
P<0.05 vs. AgNP-exposed group
P<0.05 synergistic interactions when both NPs are combined using Factorial Design
P<0.05 additive interactions when both NPs are combined using Factorial Design. TBARS, thiobarbituric acid-reactive substances; NOx, nitric oxide end products; GSH, glutathione; SOD, superoxide dismutase; CAT, catalase; GST, glutathione S-transferase; GPx, glutathione peroxidase; TAC, total antioxidant capacity; Fe2O3NPs, iron oxide nanoparticles; AgNPs, silver nanoparticles.
Figure 3.PON1 and CK-MB levels in control, Fe2O3NP-exposed group, AgNP-exposed group, and Fe2O3NPs and AgNP-coexposed group. (A) Levels of PON1 in cardiac tissue and (B) in plasma. (C) Activity of CK-MB in cardiac tissues and (D) in plasma. *P<0.05 vs. control group; #P<0.05 vs. Fe2O3NPs exposed group; $P<0.05 vs. AgNPs exposed group; &P<0.05 synergistic interactions when both NPs are combined using Factorial Design. PON1, paraoxonase; CK-MB, creatine kinase-muscle/brain; Fe2O3NP, iron oxide nanoparticle; AgNP, silver nanoparticle.
Plasma total lipid, triglyceride, cholesterol, LDL-c, vLDL-c, HDL-C, and ApoB of male rats exposed to Fe2O3NPs and AgNPs.
| Experimental groups | ||||
|---|---|---|---|---|
| Parameter (mg/dl) | Control | Fe2O3NPs | AgNPs | Fe2O3NPs+AgNPs |
| Total lipid | 505±9.0 | 610±14.8[ | 654±18.9[ | 706± 21.0[ |
| Triglycerides | 112.9±2.49 | 130.5±1.06[ | 134.8±1.17[ | 155.1±2.38[ |
| Cholesterol | 141.6±5.38 | 169.1±3.29[ | 182.6±3.10[ | 221.6±5.10[ |
| LDL-c | 50±6.9 | 88±6.9[ | 107±4.3[ | 157±7.1[ |
| VLDL-c | 23±0.5 | 26±0.5[ | 27±0.2[ | 31±0.5[ |
| HDL-c | 69±1.8 | 55±1.8[ | 48±1.9[ | 33±2.0[ |
| ApoB | 51±4.5 | 79± 4.5[ | 91±2.8[ | 127±4.6[ |
P<0.05 vs. control group
P<0.05 vs. Fe2O3NP-exposed group
P<0.05 vs. AgNP-exposed group
P<0.05 synergistic interactions when both NPs are combined using Factorial Design
P<0.05 additive interactions when both NPs are combined using Factorial Design. LDL-c, low density lipoprotein-cholesterol; vLDL-c, very low-density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; ApoB, Apolipoprotein B; Fe2O3NPs, iron oxide nanoparticles; AgNPs, silver nanoparticles.
Figure 4.Histological analysis of haematoxylin and eosin stained rat heart tissues of control, Fe2O3NP-exposed group, AgNP-exposed group, and Fe2O3NP and AgNP-coexposed group. (A) Control rats demonstrated normal myofiber cells and normal architecture. (B) Heart tissues of Fe2O3NP-exposed group revealed myocardial degeneration changes. (C) Heart of AgNP-exposed group revealed fragmentation of sacroplasm and degeneration changes in myocardial fibers. (D) Heart of the Fe2O3NP and AgNP-coexposed group revealed loss of cross striation and severe myocardial degeneration changes (magnification, ×400). Fe2O3NP, iron oxide nanoparticle; AgNP, silver nanoparticle.
Figure 5.Histological analysis of haematoxylin and eosin stained rat lung tissues of control, Fe2O3NP-exposed group, AgNP-exposed group, and Fe2O3NP and AgNP-coexposed group. (A) Lung of control rats revealed normal alveoli, bronchi lined mucous secreting columnar respiratory epithelium. (B) Lung of Fe2O3NP-exposed group demonstrated a moderate influx of polymorphs (green arrow), lymphocytes (red arrow) and macrophages (yellow arrow) into the perivascular tissue. (C) Lung of AgNP-exposed group demonstrated an influx of lymphocytes (red arrow) and histocytes (blue arrow) into the surrounding lung alveoli and perivascular cuff. (D) Lung of the Fe2O3NP and AgNP-co-exposed group demonstrated a moderate influx of polymorphs (green arrow), and lymphocytes (green arrow) into the surrounding perivascular tissue and bronchi (black arrow; magnification, ×400). Fe2O3NP, iron oxide nanoparticle; AgNP, silver nanoparticle.
Semi-quantitative analysis of heart and lung histology of male rats exposed to Fe2O3NPs and AgNPs.
| A, Heart tissue | ||||
|---|---|---|---|---|
| Experimental groups | ||||
| Parameter (mg/dl) | Control | Fe2O3NPs | AgNPs | Fe2O3NPs+AgNPs |
| Loss of cross striation | − | ++ | + | +++ |
| Fragmentation of sarcoplasm | − | ++ | + | +++ |
| Cytoplasmic vacuolization in cardiac muscles | − | ++ | + | +++ |
| Degenerative changes in myocardial fibers | − | ++ | ++ | +++ |
| Extravasations of red blood cells into long parenchyma | − | ++ | +++ | ++++ |
| Interstitial inflammation | − | ++ | ++ | ++++ |
| Alveolar wall thickening | − | ++ | +++ | ++++ |
| Collapse of terminal bronchioles | − | ++ | +++ | ++++ |
| Fibrosis | − | + | ++ | +++ |
| Alveolar macrophages | − | ++ | +++ | ++++ |
| Polymorphs infiltration | − | ++ | +++ | ++++ |
-, No change; +, mild change; ++, moderate change; +++, moderate to marked change; and ++++, marked change. Fe2O3NPs, iron oxide nanoparticles; AgNPs, silver nanoparticles.